Last Updated: November 16, 2026

Details for Patent: RE49302

« Back to Dashboard


Which drugs does patent RE49302 protect, and when does it expire?

Patent RE49302 protects VRAYLAR and is included in one NDA.

Protection for VRAYLAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-seven patent family members in thirty-three countries.

Summary for Patent: RE49302
Title:Pharmaceutical formulations containing dopamine receptor ligands
Abstract:The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described.
Inventor(s):Ranajoy Sarkar, Mahendra G. Dedhiya, Anil Chhettry
Assignee: Richter Gedeon Nyrt
Application Number:US16/384,264
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent RE49302
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;
Patent landscape, scope, and claims:

United States Patent RE49302: Cariprazine Formulation Claims, Scope, Expiry and Generic Risk

U.S. Patent RE49302 covers methods of treating schizophrenia, bipolar disorder, acute mania, and depression with low-dose solid oral cariprazine formulations. Its strongest protection is concentrated in two claim groups: pharmacokinetically defined formulations containing low-water-activity excipients, and dose-specific formulations containing pregelatinized starch. The patent does not claim cariprazine as a chemical compound. It is a formulation and method-of-treatment patent directed to the marketed Vraylar dosage range.

What drug does U.S. Patent RE49302 protect?

RE49302 protects cariprazine, also known by its chemical name trans-1-{4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl}-3,3-dimethylurea. The marketed product is cariprazine hydrochloride, sold in the United States as Vraylar by AbbVie.[1]

Attribute Patent landscape
Active ingredient Cariprazine hydrochloride
Brand Vraylar
Dosage form Solid oral capsules
Covered strengths Approximately 0.05-9 mg in claim 1; specifically 0.5, 1.5, 3, 4.5, 6 and 9 mg in dependent claims
Indications Schizophrenia, bipolar disorder, acute mania and depression
Patent type Reissue patent
Patent number U.S. RE49302
Principal protection Formulation-dependent method-of-treatment claims
Primary commercial sponsor AbbVie, following acquisition of Allergan
Originator development partner Gedeon Richter

Cariprazine is an atypical antipsychotic with dopamine D3 and D2 receptor partial agonist activity. FDA-approved Vraylar indications include schizophrenia in adults, manic or mixed episodes associated with bipolar I disorder, depressive episodes associated with bipolar I disorder, and adjunctive treatment of major depressive disorder in adults.[1]

What are the independent claims of RE49302?

RE49302 contains two independent claims.

Claim 1: pharmacokinetic and formulation-defined treatment method

Claim 1 requires all of the following:

  1. Treatment of schizophrenia, bipolar disorder, acute mania or depression.
  2. Administration of a solid oral formulation.
  3. Cariprazine or a pharmaceutically acceptable salt.
  4. A dose of approximately 0.05-9 mg.
  5. A low-water-activity excipient selected from:
    • pregelatinized starch;
    • mannitol;
    • anhydrous calcium hydrogen phosphate; or
    • mixtures of those excipients.
  6. Mean Cmax below approximately 26.3 ng/mL.
  7. Mean AUC0-inf greater than approximately 2 ng·hr/mL.
  8. Mean Tmax of approximately three hours or longer.
  9. More than 80% dissolution within approximately 60 minutes.
  10. Formulation pH of approximately 9.0-12.0.

The claim is cumulative. A product or method that satisfies only the dose and excipient limitations does not necessarily infringe claim 1 if it does not satisfy the pharmacokinetic, dissolution and pH limitations.

Claim 11: dose and pregelatinized-starch method

Claim 11 is materially broader in one respect. It requires:

  • treatment of one of the listed psychiatric conditions;
  • a solid oral formulation;
  • approximately 1.5, 3, 4.5 or 6 mg cariprazine or a pharmaceutically acceptable salt; and
  • pregelatinized starch.

Unlike claim 1, claim 11 does not expressly require the claimed Cmax, AUC, Tmax, dissolution rate or pH range. Claims 12-15 narrow claim 11 to individual dose strengths.

How do the dependent claims divide the patent scope?

Claims Required dose Excipient Additional limitations
1 Approximately 0.05-9 mg Pregelatinized starch, mannitol, anhydrous calcium hydrogen phosphate or mixtures PK, dissolution and pH requirements
2 Approximately 1.5 mg Claim 1 excipients Cmax below approximately 2.7 ng/mL; Tmax at least approximately 3 hours
3 Approximately 3 mg Claim 1 excipients Cmax below approximately 5.3 ng/mL; Tmax at least approximately 3 hours
4 Approximately 4.5 mg Claim 1 excipients Cmax below approximately 7.9 ng/mL; Tmax at least approximately 3 hours
5 Approximately 6 mg Claim 1 excipients Cmax below approximately 10.5 ng/mL; Tmax at least approximately 3 hours
6 Approximately 9 mg Claim 1 excipients AUC0-inf above approximately 180 ng·hr/mL; Tmax at least approximately 3 hours
7 Approximately 0.5 mg Claim 1 excipients Cmax below approximately 0.9 ng/mL; Tmax at least approximately 3 hours
8 Claim 1 dose range Pregelatinized starch Excipient narrowed
9 Claim 1 dose range Mannitol Excipient narrowed
10 Claim 1 dose range Anhydrous calcium hydrogen phosphate Excipient narrowed
11 1.5, 3, 4.5 or 6 mg Pregelatinized starch No express PK, dissolution or pH limitations
12 Approximately 1.5 mg Pregelatinized starch Dose-specific
13 Approximately 3 mg Pregelatinized starch Dose-specific
14 Approximately 4.5 mg Pregelatinized starch Dose-specific
15 Approximately 6 mg Pregelatinized starch Dose-specific

The commercial significance lies in claims 11-15. They map directly onto the principal Vraylar capsule strengths and avoid several of claim 1's measurable performance limitations.

What formulations are protected by RE49302?

The patent protects solid oral formulations that use a low-water-activity excipient. The specified excipients are pregelatinized starch, mannitol and anhydrous calcium hydrogen phosphate.

Pregelatinized starch

Pregelatinized starch is the most commercially important excipient under the claims because claims 11-15 expressly require it. A solid oral cariprazine product containing one of the four specified strengths and pregelatinized starch may fall within claims 11-15 even if its formulation does not exhibit the PK, pH or dissolution profile recited in claim 1.

For an ANDA applicant, excipient substitution is a potential design-around route. That route is not automatically sufficient because:

  • claim 1 also covers mannitol and anhydrous calcium hydrogen phosphate;
  • mixtures may be covered;
  • infringement may turn on the complete formulation and not the applicant's preferred excipient description;
  • formulation components can be present as processing aids, diluents or functional excipients depending on the specification and claim construction.

Mannitol and anhydrous calcium hydrogen phosphate

Mannitol and anhydrous calcium hydrogen phosphate are expressly covered by claims 1 and 9-10. They are not expressly included in the narrower independent claim 11.

A formulation using mannitol or anhydrous calcium hydrogen phosphate therefore presents a different risk profile from a pregelatinized-starch formulation. It may avoid claims 11-15 while still implicating claim 1 if the PK, dissolution and pH limitations are met.

pH and dissolution

Claim 1 requires a formulation pH of approximately 9.0-12.0 and more than 80% dissolution within approximately 60 minutes after administration of the composition. These limitations create evidentiary issues:

  • pH must be measured using a defined test method;
  • dissolution depends on apparatus, medium, agitation, sampling time and acceptance criteria;
  • "more than about 80%" creates a numerical boundary subject to claim construction;
  • the claim does not merely require rapid dissolution in vitro; it also requires a specified in vivo plasma profile.

A generic formulation can be outside claim 1 if it fails any one of those limitations. That does not resolve risk under claims 11-15.

How strong is the patent estate for Vraylar and cariprazine?

RE49302 is a targeted patent rather than a basic compound patent. Its strength depends on the formulation used by the generic applicant and on whether the claims are listed for the relevant Vraylar products in the FDA Orange Book.

Strengths

  1. Direct coverage of marketed strengths. Claims 11-15 cover 1.5, 3, 4.5 and 6 mg, which correspond to the core Vraylar capsule strengths.
  2. No express PK limitation in claims 11-15. This makes the narrower claim set easier to assert than claim 1 if a generic uses pregelatinized starch.
  3. Method-of-treatment coverage. An ANDA proposed label that instructs use for the claimed conditions can create induced-infringement exposure if the formulation limitations are met.
  4. Multiple excipient pathways. Claim 1 reaches formulations using any one of three named excipients or mixtures.
  5. Reissue status. The reissue patent is enforceable according to its issued claims, subject to reissue-specific limits and ordinary validity defenses.[2]

Limitations

  1. No chemical-compound claim. RE49302 does not prevent production of cariprazine itself.
  2. No universal composition claim. The claims require treatment of specified conditions.
  3. Excipient dependence. A formulation that uses none of the listed low-water-activity excipients may avoid the literal scope of claim 1.
  4. Dose specificity. Claims 11-15 focus on four strengths. A product using another strength may avoid those claims, although claim 1 has a wider dose range.
  5. Potential proof burden for claim 1. Cmax, AUC, Tmax, dissolution and pH must be established against the claim limitations.
  6. Use-code dependence. Patent-listing and induced-infringement exposure depend on the approved labeling and the use code associated with the patent.

Overall, the patent is stronger against a formulation that copies the Vraylar excipient system and approved dose strengths than against a generic that uses a materially different excipient architecture.

When does RE49302 lose exclusivity?

The controlling patent term is the term of the original patent from which the reissue derives, subject to any applicable patent-term adjustment, terminal disclaimer or other term record.[2] A reissue does not ordinarily create a new patent term independent of the original patent.

RE49302 is associated with the cariprazine formulation patent family and has been publicly identified in connection with Vraylar patent protection. The operative expiration date should be taken from the USPTO patent record and the current FDA Orange Book listing because the expiration calculation can depend on the original patent term, patent-term adjustment and any terminal disclaimer.[2,3]

Exclusivity category Relevance to Vraylar
New chemical entity exclusivity Expired after the statutory five-year period
Pediatric exclusivity May have extended listed patent and regulatory protection, depending on the product's FDA record
RE49302 patent term Controls only the claims of the patent and expires with the underlying patent term
Regulatory exclusivity Separate from patent exclusivity
Generic entry Depends on all unexpired Orange Book-listed patents, ANDA certification and litigation outcomes

The FDA approved Vraylar in 2015. The initial five-year NCE exclusivity period therefore did not remain the primary barrier after 2020. Current market protection is driven mainly by patents, including formulation and method-of-use patents, rather than by NCE exclusivity.[1,3]

What is the Orange Book status of RE49302?

The Orange Book is the controlling FDA source for patents submitted by the NDA holder and associated with approved products. A listed patent can require an ANDA applicant to submit a Paragraph IV certification if the applicant asserts that the patent is invalid, unenforceable or not infringed.[3]

RE49302 should be analyzed together with the complete Vraylar patent listing, not in isolation. The relevant questions are:

  • whether RE49302 is listed against each Vraylar dosage form;
  • which approved use code is associated with the patent;
  • whether the listing covers all strengths or only certain strengths;
  • whether the patent has been delisted, expired or replaced by a reissue listing;
  • whether FDA has imposed a regulatory stay following a timely infringement action.

The claim language supplied for RE49302 indicates coverage directed to treatment of schizophrenia, bipolar disorder, acute mania and depression. That scope is broader than a single indication, but the enforceability of any particular use depends on the approved labeling and the listing data.

Which companies are challenging Vraylar patents?

A patent challenge requires a specific ANDA, Paragraph IV certification, district-court complaint or inter partes review record. The RE49302 claims alone do not establish that a particular company has filed a challenge.

The principal potential challengers are generic manufacturers seeking approval for cariprazine capsules, including large ANDA sponsors and specialty generic companies. Their likely strategies are:

Challenge strategy Target
Paragraph III certification Wait for patent expiration
Paragraph IV certification Assert invalidity, unenforceability or noninfringement
Formulation design-around Avoid pregelatinized starch, mannitol and anhydrous calcium hydrogen phosphate
Dose design-around Use a strength outside claims 11-15
PK design-around Avoid the claimed Cmax, AUC or Tmax profile
Label carve-out Remove a patented indication where FDA permits a section viii statement
IPR or post-grant challenge Attack patentability before the Patent Trial and Appeal Board

For RE49302 specifically, a Paragraph IV case would likely focus on written description, enablement, indefiniteness, obviousness, anticipation and infringement. The broadest practical defense would be a formulation that does not contain a listed excipient and does not satisfy the claim 1 performance limitations.

What patent litigation affects cariprazine generic entry?

Vraylar generic-entry litigation would typically arise under the Hatch-Waxman framework. After an ANDA applicant provides a Paragraph IV notice, the NDA holder may sue within 45 days. A timely suit can trigger a 30-month FDA approval stay, subject to statutory exceptions and court action.[4]

The litigation risk is strongest when:

  • the proposed generic uses pregelatinized starch;
  • the proposed strengths are 1.5, 3, 4.5 or 6 mg;
  • the ANDA label includes all four claimed psychiatric conditions;
  • the formulation's dissolution and pH data fall within claim 1;
  • the applicant's proposed product is materially similar to the commercial Vraylar formulation.

A generic applicant could reduce exposure through a non-infringing formulation, a section viii label carve-out, a Paragraph III certification, or an agreement resolving litigation before judgment. A settlement may include a deferred launch date, a license, an authorized-generic arrangement or restrictions on the scope of the launch. No settlement terms should be inferred from the existence of the patent alone.

Does RE49302 create biosimilar risk?

No. Cariprazine is a chemically synthesized small molecule, not a biologic. The relevant competitors are ANDA-approved generic products, not biosimilars under the Public Health Service Act.

The applicable regulatory pathway is section 505(j) of the Federal Food, Drug, and Cosmetic Act. A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, subject to FDA requirements for strength, dosage form, route and labeling.[4]

What manufacturing and intellectual-property barriers remain?

The chemical synthesis of cariprazine is separate from the formulation claims in RE49302. A manufacturer may be able to produce the active pharmaceutical ingredient without practicing this patent, but commercial launch requires control of several additional risk areas:

  • active-ingredient process patents;
  • salt, polymorph or crystalline-form patents;
  • formulation patents;
  • capsule and excipient composition;
  • manufacturing-process patents;
  • analytical methods;
  • regulatory exclusivity;
  • trademark and trade-dress restrictions;
  • controlled supply of qualified cariprazine API.

RE49302 does not claim the API manufacturing process. Its commercial leverage is therefore concentrated at the finished-product stage.

How does RE49302 compare with a compound patent?

Issue Compound patent RE49302
Protects cariprazine molecule Yes No
Protects all dosage forms Potentially No
Requires specified excipient Usually no Yes
Requires patient treatment Usually no Yes
Covers marketed doses Broadly, if within claims Yes, particularly 1.5-6 mg
Design-around potential Low during term Moderate
Main generic defense Invalidity or expiration Formulation noninfringement plus validity defenses
Importance to launch timing Fundamental Potentially significant as a later-life barrier

A compound patent usually presents the strongest exclusionary right. RE49302 is narrower but commercially relevant because it targets the final dosage form used in the approved product.

What generic launch scenarios exist for cariprazine?

Scenario 1: copied formulation and Paragraph IV challenge

A generic applicant copies the relevant excipient system, files a Paragraph IV certification and litigates. This creates the highest direct infringement risk under claims 11-15.

Scenario 2: non-pregelatinized formulation

The applicant avoids pregelatinized starch and uses a different excipient system. Risk under claims 11-15 declines, but claim 1 remains relevant if mannitol or anhydrous calcium hydrogen phosphate is used and the PK, pH and dissolution limits are met.

Scenario 3: section viii carve-out

The applicant removes one or more patented indications from its labeling. This approach may reduce method-of-use exposure but cannot avoid formulation limitations that are practiced for an uncarved indication.

Scenario 4: delayed launch after settlement

The applicant accepts a later entry date in exchange for resolution of patent litigation or a license. The commercial effect depends on whether the settlement permits an authorized generic or limits other challengers.

Scenario 5: launch after patent expiry

The applicant files a Paragraph III certification or waits for all relevant patent barriers to expire. This provides the lowest litigation risk but sacrifices first-challenger economics.

What is the revenue exposure from RE49302?

Vraylar is a high-value branded antipsychotic, and generic entry would expose U.S. revenue through price erosion, formulary substitution and volume migration. The exact revenue exposure depends on:

  • the date of first generic approval;
  • the number of approved generic suppliers;
  • whether 180-day exclusivity applies;
  • the availability of authorized generic supply;
  • payer substitution;
  • the number of indications included in the generic label;
  • the survival of other Vraylar patents;
  • the launch strength mix.

RE49302 is unlikely to determine the entire Vraylar exclusivity period by itself. Its effect is to increase the legal and technical cost of launching a formulation that closely tracks the branded product.

Key Takeaways

  • RE49302 is a cariprazine formulation and method-of-treatment patent, not a compound patent.
  • Claim 1 requires a low-water-activity excipient, defined PK exposure, rapid dissolution and alkaline pH.
  • Claims 11-15 are commercially important because they cover 1.5, 3, 4.5 and 6 mg cariprazine formulations containing pregelatinized starch.
  • A generic using pregelatinized starch at those strengths faces the clearest infringement risk.
  • Mannitol and anhydrous calcium hydrogen phosphate can implicate claim 1 but are not expressly included in claims 11-15.
  • Cariprazine faces generic, not biosimilar, competition.
  • The reissue term follows the underlying original patent term and must be read with the USPTO record and Orange Book listing.
  • Generic launch timing depends on the full Vraylar patent estate, Paragraph IV filings, litigation stays and any settlement agreements.

FAQs

Can a cariprazine generic avoid RE49302 by changing the capsule color?

No. Capsule color is not a substantive limitation in the supplied claims. The relevant variables are the active ingredient, dose, excipient, treatment method and, for claim 1, PK, dissolution and pH performance.

Does claim 11 require the formulation to have a pH between 9.0 and 12.0?

No. The express pH limitation appears in claim 1. Claims 11-15 require the specified dose and pregelatinized starch but do not recite the claim 1 pH range.

Is a 9 mg cariprazine product covered by claims 11-15?

No. Claims 11-15 identify approximately 1.5, 3, 4.5 or 6 mg. A 9 mg formulation may still fall within claim 1 if all of claim 1's limitations are met, including the AUC and Tmax requirements.

Can an ANDA applicant omit depression from a cariprazine label?

Potentially, if FDA permits a valid section viii carve-out and the remaining label does not induce use covered by the patent. The effect depends on the approved use code and the final labeling.

Does RE49302 block manufacture of cariprazine API?

No. The supplied claims require administration of a finished solid oral formulation. They do not claim the chemical synthesis or manufacture of cariprazine API.

References

  1. U.S. Food and Drug Administration. (2024). Vraylar (cariprazine) prescribing information. FDA.
  2. United States Patent and Trademark Office. (2023). U.S. Patent No. RE49,302, reissue patent record and prosecution history. USPTO Patent Center.
  3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
  4. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. FDA.
  5. United States Code. (2024). 35 U.S.C. §§ 251, 271, 282. Cornell Legal Information Institute.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent RE49302

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-001 Sep 17, 2015 RX Yes Yes RE49302*PED ⤷  Start Trial Y ⤷  Start Trial
Abbvie VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-002 Sep 17, 2015 RX Yes No RE49302*PED ⤷  Start Trial Y ⤷  Start Trial
Abbvie VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-003 Sep 17, 2015 RX Yes No RE49302*PED ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.